European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 ...

So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Novartis said it plans to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well ...

The Federal Circuit reversed finding sufficient written description. The Federal Circuit explained that the written description requirement pertains only to the claims themselves and the construction ...

Sacubitril, valsartan; 6mg/6mg, 15mg/16mg; oral pellets in caps. Entresto Sprinkle is supplied as film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule in the ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

Novartis has over 3,000 employees working at its campus in East Hanover, and 12,000 employees nationwide, said Novartis ...

Story continues below photo gallery. This round of layoffs was triggered in part by the upcoming patent expiration for Novartis’ Entresto, its heart condition medication, according to the company.